These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34765617)

  • 1. RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europe-Why the European Union Should Invest More!
    Goldsobel G; von Herrath C; Schlickeiser S; Brindle N; Stähler F; Reinke P; Aberman Z; Ofir R; Dessole G; Benvenuti S; Neves NM; Reis RL; Moll G; Volk HD
    Front Med (Lausanne); 2021; 8():739987. PubMed ID: 34765617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union.
    Beattie S;
    Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
    Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
    Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgery Versus ATMPs: An Example From Ophthalmology.
    Magrelli FM; Merra A; Pellegrini G
    Front Bioeng Biotechnol; 2020; 8():440. PubMed ID: 32587848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries.
    Coppens DGM; Hoekman J; De Bruin ML; Slaper-Cortenbach ICM; Leufkens HGM; Meij P; Gardarsdottir H
    Cytotherapy; 2020 Oct; 22(10):592-600. PubMed ID: 32563611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-based medicinal products approved in the European Union: current evidence and perspectives.
    Bellino S; La Salvia A; Cometa MF; Botta R
    Front Pharmacol; 2023; 14():1200808. PubMed ID: 37583902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
    Ronco V; Dilecce M; Lanati E; Canonico PL; Jommi C
    J Pharm Policy Pract; 2021 Mar; 14(1):30. PubMed ID: 33741076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products.
    Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ
    Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?
    Boráň T; Menezes-Ferreira M; Reischl I; Celis P; Ferry N; Gänsbacher B; Krafft H; Lipucci di Paola M; Sladowski D; Salmikangas P
    Hum Gene Ther Clin Dev; 2017 Sep; 28(3):126-135. PubMed ID: 28510497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy.
    Rivetti di Val Cervo P; Alessi E; Lastella M; La Greca A; Trotta F
    BioDrugs; 2024 Nov; 38(6):831-844. PubMed ID: 39404995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Current State of Advanced Therapy Medicinal Products in the Czech Republic.
    Kočí Z; Boráň T; Krůpa P; Kubinová Š
    Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced therapy medicinal products: current and future perspectives.
    Hanna E; Rémuzat C; Auquier P; Toumi M
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of advanced therapy medicinal products in Europe and the role of academia.
    Pearce KF; Hildebrandt M; Greinix H; Scheding S; Koehl U; Worel N; Apperley J; Edinger M; Hauser A; Mischak-Weissinger E; Dickinson AM; Lowdell MW
    Cytotherapy; 2014 Mar; 16(3):289-97. PubMed ID: 24113428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine.
    Goula A; Gkioka V; Michalopoulos E; Katsimpoulas M; Noutsias M; Sarri EF; Stavropoulos C; Kostakis A
    J Clin Med Res; 2020 Dec; 12(12):780-786. PubMed ID: 33447311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
    Iglesias-López C; Agustí A; Vallano A; Obach M
    Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU.
    Fürst-Ladani S; Bührer A; Fürst W; Schober-Ladani N
    Handb Exp Pharmacol; 2024; 284():367-387. PubMed ID: 37017789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Landscape of Brazilian research and development public funding in advanced therapies: lessons learned and a roadmap for middle-income economies.
    Sachetti CG; Júnior AB; de Carvalho ACC; Angulo-Tuesta A; da Silva EN
    Cytotherapy; 2022 Nov; 24(11):1158-1165. PubMed ID: 35945103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.